Compare Abbott Laboratories (ABT) vs Kohl's Corporation (KSS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Kohl's Corporation — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Kohl's Corporation trades at $15.97 (market cap $1.90B). The key difference: Abbott Laboratories is far larger — about 87.9× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.98%). Which is the better fit depends on your goals.
| ABT | KSS | |
|---|---|---|
Market Cap | $166.94B | $1.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $24.71 |
52-Week Low | $82.57 | $9.08 |
Enterprise Value | $193.69B | $8.00B |
Dividend Yield | 2.63% | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Kohl's (KSS) trades at $16.76, down 7.86% on the day, with the stock showing mixed technical signals amid a broader turnaround effort. The company demonstrates improving fundamentals with recent earnings beats and proprietary brand growth, though revenue continues to decline. Valuation metrics appear attractive with a P/E of 7.1 and P/S of 0.12, while technical indicators show bullish moving averages but neutral oscillators.
Kohl's presents a compelling value opportunity with strong proprietary brand momentum and cost controls, though execution risks remain high amid declining sales and intense retail competition. The stock's current price aligns with analyst consensus targets, suggesting limited near-term upside without clearer evidence of sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
